Results 91 to 100 of about 86,566 (299)

HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors

eLife, 2019
Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are a promising new class of antiretroviral agents that disrupt proper viral maturation by inducing hyper-multimerization of IN.
Pratibha C. Koneru, A. C. Francis, N. Deng, Stephanie V. Rebensburg, Ashley C Hoyte, J. Lindenberger, Daniel Adu-Ampratwum, Ross C. Larue, M. Wempe, A. Engelman, D. Lyumkis, J. Fuchs, R. Levy, G. Melikyan, M. Kvaratskhelia   +14 more
semanticscholar   +1 more source

Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy

HIV Medicine, EarlyView.
Abstract Objective Evaluate factors associated with discontinuation of long‐acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) and describe virologic outcomes in those that returned to oral antiretroviral therapy (ART). Methods This is a retrospective cohort study at a single‐centre primary care HIV clinic.
Tali Faggiano, Jeffrey Yin, Nimish Patel, Afsana Karim, Kari Abulhosn, Laura Bamford, Lucas Hill   +6 more
wiley   +1 more source

The mechanism of H171T resistance reveals the importance of Nδ-protonated His171 for the binding of allosteric inhibitor BI-D to HIV-1 integrase [PDF]

, 2015
Background: Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are an important new class of anti-HIV-1 agents. ALLINIs bind at the IN catalytic core domain (CCD) dimer interface occupying the principal binding pocket of its cellular cofactor LEDGF/p75.
Deng, Nanjie, Engelman, Alan, Fadel, Hind J, Feng, Lei, Fuchs, James R, Jena, Nivedita, Jurado, Kellie A, Kessl, Jacques J, Kvaratskhelia, Mamuka, Larue, Ross C, Levy, Ronald M, Patel, Pratiq A, Poeschla, Eric, Shkriabai, Nikoloz, Slaughter, Alison   +14 more
core   +1 more source

HIV drug resistance against strand transfer integrase inhibitors

Retrovirology, 2017
Integrase strand transfer inhibitors (INSTIs) are the newest class of antiretroviral drugs to be approved for treatment and act by inhibiting the essential HIV protein integrase from inserting the viral DNA genome into the host cell’s chromatin.
Kaitlin Anstett, B. Brenner, T. Mesplède, M. Wainberg   +3 more
semanticscholar   +1 more source

Polypharmacy in HIV: Rethinking what counts and why it matters

HIV Medicine, EarlyView.
Abstract Polypharmacy, the concurrent use of multiple medications, presents a growing challenge in HIV care as people living with HIV age and experience earlier onset of age‐related co‐morbidities. However, how polypharmacy is defined and assessed in HIV research remains inconsistent.
Luxsena Sukumaran, Alan Winston, Catia Marzolini, Saye Khoo, Marta Boffito, Nadia Naous, Caroline A. Sabin   +6 more
wiley   +1 more source

Discovery of Novel Integrase Inhibitors Acting outside the Active Site Through High-Throughput Screening

Molecules, 2019
Currently, an increasing number of drugs are becoming available to clinics for the treatment of HIV infection. Even if this targeted therapy is highly effective at suppressing viral replication, caregivers are facing growing therapeutic failures in ...
Cindy Aknin, Elena A. Smith, Christophe Marchand, Marie-Line Andreola, Yves Pommier, Mathieu Metifiot   +5 more
doaj   +1 more source

Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes [PDF]

, 2014
To evaluate the replication capacity and phenotypic susceptibility to dolutegravir and raltegravir of wild-type and raltegravir-resistant HIV-1 strains in several cellular ...
Calvez, V, Ceccherini-Silberstein, F, Cortese, Mf, di Santo, F, Fabeni, L, Fedele, V, Malet, I, Marcelin, A-, Perno, CF, Pollicita, M, Surdo, M, Svicher, V   +11 more
core   +1 more source

Temporal network analysis of comorbidities among people with HIV in South Carolina

HIV Medicine, EarlyView.
Abstract Introduction People with HIV experience a high rate of comorbidities that can complicate their health outcomes. Understanding the prevalence, interrelationships and temporal development of these comorbidities is crucial for improving health management and quality of life for people with HIV.
Yunqing Ma, Matthew Lohman, Monique J. Brown, Yichen Li, Xiaoming Li, Bankole Olatosi, Jiajia Zhang   +6 more
wiley   +1 more source

Treatment with integrase inhibitors alters SARS‐CoV‐2 neutralization levels measured with HIV‐based pseudotypes in people living with HIV [PDF]

, 2023
Erick De La Torre Tarazona, Alba González‐Robles, Almudena Cascajero, Paloma Jiménez, José M. Miró, Sonsoles Sánchez‐Palomino, José Alcamı́, María J. Buzón, Javier García‐Pérez   +8 more
openalex   +1 more source

LDLR-Gene therapy for familial hypercholesterolaemia: Problems, progress, and perspectives [PDF]

, 2010
Coronary artery diseases (CAD) inflict a heavy economical and social burden on most populations and contribute significantly to their morbidity and mortality rates.
Al-Allaf, FA, Coutelle, C, David, A, Harbottle, R, Themis, M, Waddington, SN   +5 more
core   +3 more sources